ImmunOnsia Appoints Former National Cancer Center Professor Kim Heung-tae as New CEO

Kim Heung-tae Appointed as New CEO of ImmunOnsia

[Asia Economy Reporter Kim Ji-hee] ImmunOncia announced on the 1st that it has appointed former National Cancer Center professor Kim Heung-tae as its new CEO.

New CEO Kim Heung-tae is an expert in lung cancer and esophageal cancer. He graduated from Seoul National University College of Medicine and earned a Ph.D. in medicine from the same graduate school. He served as a professor at Dankook University College of Medicine and trained at the U.S. National Cancer Institute (NCI). Afterwards, he held key positions at the National Cancer Center, including Director of the Clinical Trial Center, Director of the Lung Cancer Center, Director of Planning and Coordination, and Deputy Director, playing a central role in the overall management of the cancer-specialized medical institution.

He also served as the head of the Cancer Conquest Promotion Planning Group, overseeing the national cancer research and development project for four years, contributing significantly to the remarkable advancement of Korea's cancer research level. Based on approximately 33 years of experience in clinical practice, research, and management, he is recognized for having a broad network across academia, the medical community, and government agencies.

A company official said, “With CEO Kim’s joining, we expect to achieve good results in the ongoing clinical trials and gain further momentum in expanding new pipelines.”

ImmunOncia is an immuno-oncology specialized bio-venture jointly established by Yuhan Corporation and Sorrento Therapeutics, a U.S. Nasdaq-listed company. In March this year, it licensed the CD47 antibody anticancer drug candidate ‘IMC-002’ to a next-generation immuno-oncology developer in China for approximately 540 billion KRW.

This content was produced with the assistance of AI translation services.